drugset / Trial / NCT06836063
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Timeline
- Start
- 2025-07-15
- Primary completion
- 2026-02-23
- Completion
- 2026-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ropanicant | Small molecule | — | — |